Nang Kuang Pharmaceutical Co., Ltd. (1752.TW)
TWD 36.4
(-0.41%)
TWD 36.4
(-0.41%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.15 Billion TWD | 10.81% |
| 2022 | 1.94 Billion TWD | 9.01% |
| 2021 | 1.78 Billion TWD | 1.44% |
| 2020 | 1.75 Billion TWD | -0.42% |
| 2019 | 1.76 Billion TWD | 14.54% |
| 2018 | 1.53 Billion TWD | 2.31% |
| 2017 | 1.5 Billion TWD | -2.97% |
| 2016 | 1.54 Billion TWD | 1.93% |
| 2015 | 1.52 Billion TWD | 19.07% |
| 2014 | 1.27 Billion TWD | 26.05% |
| 2013 | 1.01 Billion TWD | 6.38% |
| 2012 | 952.13 Million TWD | 17.1% |
| 2011 | 813.12 Million TWD | 24.55% |
| 2010 | 652.82 Million TWD | -2.57% |
| 2009 | 670.02 Million TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 528.46 Million TWD | 2.36% |
| 2024 Q2 | 512.29 Million TWD | -3.06% |
| 2023 Q4 | 516.3 Million TWD | -3.86% |
| 2023 Q3 | 537.05 Million TWD | 2.54% |
| 2023 FY | 2.15 Billion TWD | 10.81% |
| 2023 Q1 | 573.08 Million TWD | -4.65% |
| 2023 Q2 | 523.77 Million TWD | -8.6% |
| 2022 Q1 | 375.75 Million TWD | -16.39% |
| 2022 FY | 1.94 Billion TWD | 9.01% |
| 2022 Q4 | 601.04 Million TWD | 22.45% |
| 2022 Q3 | 490.83 Million TWD | 3.8% |
| 2022 Q2 | 472.85 Million TWD | 25.84% |
| 2021 Q4 | 449.39 Million TWD | -3.34% |
| 2021 Q1 | 423.09 Million TWD | -1.09% |
| 2021 Q2 | 442.7 Million TWD | 4.63% |
| 2021 FY | 1.78 Billion TWD | 1.44% |
| 2021 Q3 | 464.9 Million TWD | 5.01% |
| 2020 Q3 | 424.83 Million TWD | 0.59% |
| 2020 Q2 | 422.35 Million TWD | -11.99% |
| 2020 Q4 | 427.75 Million TWD | 0.69% |
| 2020 Q1 | 479.88 Million TWD | -3.86% |
| 2020 FY | 1.75 Billion TWD | -0.42% |
| 2019 Q4 | 499.14 Million TWD | 6.25% |
| 2019 Q2 | 416.25 Million TWD | 10.38% |
| 2019 Q1 | 377.09 Million TWD | -8.16% |
| 2019 FY | 1.76 Billion TWD | 14.54% |
| 2019 Q3 | 469.76 Million TWD | 12.86% |
| 2018 FY | 1.53 Billion TWD | 2.31% |
| 2018 Q4 | 410.61 Million TWD | 14.44% |
| 2018 Q3 | 358.8 Million TWD | -8.06% |
| 2018 Q2 | 390.24 Million TWD | 3.0% |
| 2018 Q1 | 378.87 Million TWD | -13.22% |
| 2017 FY | 1.5 Billion TWD | -2.97% |
| 2017 Q4 | 436.57 Million TWD | 18.37% |
| 2017 Q3 | 368.81 Million TWD | 6.28% |
| 2017 Q1 | 351.28 Million TWD | -0.31% |
| 2017 Q2 | 347.04 Million TWD | -1.21% |
| 2016 FY | 1.54 Billion TWD | 1.93% |
| 2016 Q4 | 352.36 Million TWD | -8.12% |
| 2016 Q3 | 383.5 Million TWD | -5.6% |
| 2016 Q2 | 406.25 Million TWD | -0.33% |
| 2016 Q1 | 407.58 Million TWD | -0.86% |
| 2015 Q2 | 375.94 Million TWD | 5.19% |
| 2015 Q3 | 375.84 Million TWD | -0.03% |
| 2015 Q4 | 411.13 Million TWD | 9.39% |
| 2015 FY | 1.52 Billion TWD | 19.07% |
| 2015 Q1 | 357.4 Million TWD | -0.42% |
| 2014 Q3 | 358.36 Million TWD | 24.2% |
| 2014 Q1 | 270.95 Million TWD | -9.58% |
| 2014 FY | 1.27 Billion TWD | 26.05% |
| 2014 Q4 | 358.9 Million TWD | 0.15% |
| 2014 Q2 | 288.54 Million TWD | 6.49% |
| 2013 Q2 | 238.5 Million TWD | 4.87% |
| 2013 Q4 | 299.66 Million TWD | 21.17% |
| 2013 FY | 1.01 Billion TWD | 6.38% |
| 2013 Q1 | 227.43 Million TWD | -11.52% |
| 2013 Q3 | 247.31 Million TWD | 3.69% |
| 2012 Q1 | 233.09 Million TWD | 13.31% |
| 2012 Q2 | 231.6 Million TWD | -0.64% |
| 2012 FY | 952.13 Million TWD | 17.1% |
| 2012 Q3 | 230.39 Million TWD | -0.52% |
| 2012 Q4 | 257.05 Million TWD | 11.57% |
| 2011 Q2 | 192.31 Million TWD | -3.11% |
| 2011 Q1 | 198.49 Million TWD | 21.55% |
| 2011 Q4 | 205.71 Million TWD | -5.02% |
| 2011 Q3 | 216.59 Million TWD | 12.62% |
| 2011 FY | 813.12 Million TWD | 24.55% |
| 2010 Q3 | 168.9 Million TWD | 4.04% |
| 2010 Q2 | 162.35 Million TWD | 2.58% |
| 2010 Q1 | 158.26 Million TWD | 0.0% |
| 2010 Q4 | 163.29 Million TWD | -3.32% |
| 2010 FY | 652.82 Million TWD | -2.57% |
| 2009 FY | 670.02 Million TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Maxigen Biotech Inc. | 622.11 Million TWD | -245.632% |
| SciVision Biotech Inc. | 712.98 Million TWD | -201.58% |
| Bionime Corporation | 1.75 Billion TWD | -22.481% |
| Pegavision Corporation | 6.78 Billion TWD | 68.332% |
| Visco Vision Inc. | 2.39 Billion TWD | 10.32% |